Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.

Jensen, Poul Erik H; Warnke, Clemens; Ingenhoven, Kathleen; Piccoli, Luca; Gasis, Marcia; Hermanrud, Christina; Fernandez-Rodriguez, Blanca M; Ryner, Malin; Kramer, Daniel; Link, Jenny; Ramanujam, Ryan; Auer, Michael; Buck, Dorothea; Grummel, Verena; Bertotti, Elisa; Fissolo, Nicolas; Oliver-Martos, Begoña; Nytrova, Petra; Khalil, Michael; Guger, Michael; Rathmaier, Sandra; Sievers-Stober, Claudia; Lindberg, Raija L P; Hässler, Signe; Bachelet, Delphine; Aktas, Orhan; Donnellan, Naoimh; Lawton, Andy; Hemmer, Bernhard; Havrdova, Eva Kubala; Kieseier, Bernd; Hartung, Hans-Peter; Comabella, Manuel; Montalban, Xavier; Derfuss, Tobias; Sellebjerg, Finn; Dönnes, Pierre; Pallardy, Marc; Spindeldreher, Sebastian; Broet, Philippe; Deisenhammer, Florian; Fogdell-Hahn, Anna; Sorensen, Per Soelberg     «

Jensen, Poul Erik H; Warnke, Clemens; Ingenhoven, Kathleen; Piccoli, Luca; Gasis, Marcia; Hermanrud, Christina; Fernandez-Rodriguez, Blanca M; Ryner, Malin; Kramer, Daniel; Link, Jenny; Ramanujam, Ryan; Auer, Michael; Buck, Dorothea; Grummel, Verena; Bertotti, Elisa; Fissolo, Nicolas; Oliver-Martos, Begoña; Nytrova, Petra; Khalil, Michael; Guger, Michael; Rathmaier, Sandra; Sievers-Stober, Claudia; Lindberg, Raija L P; Hässler, Signe; Bachelet, Delphine; Aktas, Orhan; Donnellan, Naoimh; Lawton,...     »

Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.      «

Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection...     »